Clinical Trial

Cardiac Transplant Metabolomics With and Without Rejection

Study acronym: ANTIPARTICLE
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 23, 2024 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
Patient who received a heart transplant may develop organ rejection. Currently, an invasive biopsy of the heart needs to be performed to diagnose rejection. The purpose of this research study is to identify novel metabolic biomarkers that can be developed into a blood test that can identify signs of rejection without doing a heart biopsy.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05772442
Lead Sponsor Western University, Canada
Collaborators: Canadian Cardiovascular Society, Bayer, University of Alberta, Queen's University
Conditions Heart Transplant Rejection
Enrollment 100 participants
Start Date 2024-07
Primary Completion 2025-10 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2024-07-23